Pitt Street Research | Stock research
Proteomics International Laboratories.png

Proteomics International Laboratories

Proteomics International Laboratories (ASX: PIQ) is a biotech company that is developing precision diagnostic medical tests that identify protein biomarkers via blood samples and consequently, medical indications. The company is poised to commercialise 3 of them in the first half of CY25 (1H25) – PromarkerD for Diabetic Kidney Disease (DKD), PromarkerEndo for Endometriosis and PromarkerEso and Esophageal cancer – all named after the Promarker platform these tests were developed from.

Proteomics International Laboratories (ASX: PIQ)

 

Proteomics International Laboratories (ASX: PIQ) is a biotech company that is developing precision diagnostic medical tests that identify protein biomarkers via blood samples and consequently, medical indications. The company is poised to commercialise 3 of them in the first half of CY25 (1H25) – PromarkerD for Diabetic Kidney Disease (DKD), PromarkerEndo for Endometriosis and PromarkerEso and Esophageal cancer – all named after the Promarker platform these tests were developed from.

On 5 June 2025, we spoke with Dr. Richard Lipscombe, CEO of Proteomics International Laboratories (ASX: PIQ), about the strong commercial prospects of his PromarkerD diagnostic for kidney disease now that the product is available for clinical use. We also spoke about the valuable pipeline that it's building, with diagnostics for endometriosis and esophageal cancer. Proteomics' platform, allowing the easy characterisation of proteins, has considerable upside that is only now being tapped.